FDA Approves Degevma Biosimilar for Cancer-Related Bone Complications

The U.S. Food and Drug Administration has granted approval to Degevma, a biosimilar to Amgen's Xgeva. This new medication is indicated for preventing bone complications in adults with advanced cancer that has metastasized to the bone, treating giant cell tumor of bone in adults and skeletally mature adolescents, and managing hypercalcemia of malignancy. This approval offers an additional treatment option for these conditions.